Objectives: Surgical resection for locally advanced rectal adenocarcinoma commonly occurs 6 to 10 weeks after completion of neoadjuvant chemoradiation (nCRT). We sought to determine the optimal timing of surgery related to the pathologic complete response rate and survival endpoints.
C
olorectal cancer is the fourth most common cancer worldwide and the third most common in the United States. In locally advanced rectal adenocarcinoma (cT3-4N0 or N + disease), chemoradiation (CRT) has long been a standard component of care. In the last decade, most oncologists have shifted their practice to deliver CRT preoperatively, based on the results of multiple randomized trials comparing preoperative versus postoperative approaches, including the German Rectal Cancer Trial, as well as NSABP-R03, FFCD 9203, and EORTC 22921. [1] [2] [3] [4] [5] These trials informed us that preoperative CRT results not only in improved outcomes such as locoregional control (LRC) and disease-free survival (DFS), but also reduces toxicity compared with postoperative CRT.
Pathologic complete response (pCR) after neoadjuvant chemoradiation (nCRT) appears to be associated with improved outcomes (ie, decreased locoregional failure, improved DFS, and overall survival [OS] ) in rectal cancer and other types of gastrointestinal cancer, including esophageal cancer. 6 A systemic review and meta-analysis was performed by Martin et al 7 on 16 studies involving 3363 patients and showed that pCR after nCRT is associated with increased LRC, distant control, DFS, and OS. Thus, investigators have speculated that 1 strategy to prolong survival might be to improve pCR rates after neoadjuvant therapy. Others have proposed that achieving pCR might also allow patients to forgo adjuvant chemotherapy. 6 Furthermore, achieving a clinical complete response in selected patients might allow for nonoperative management with close observation, and surgery reserved for recurrent disease. [8] [9] [10] Retrospective analyses have suggested that delaying surgical resection longer than the commonly planned 6 to 8 weeks after nCRT appears to result in improved pCR rates with increased tumor downstaging. [11] [12] [13] [14] [15] [16] [17] Thus, several investigators have proposed that delaying surgical resection beyond 8 weeks could increase pCR rates as a means to improving prognostication, tumor control, and outcomes. Recently, an analysis was performed on 1593 patients from a Dutch series, which demonstrated that delaying surgery to 10 to 11 weeks after radiation results in higher pCR rates. 18 However, they noted incidentally that higher metastasis rates were observed when surgery was delayed beyond 9 weeks. In this study, we performed a singleinstitution retrospective analysis of patients treated with nCRT and surgery to assess the role of timing of surgery after nCRT to determine whether delaying surgery increases rates of pCR or alters clinical outcomes such as metastasis.
MATERIALS AND METHODS

Patient Population
Retrospective analysis was performed on 118 consecutive patients at The Ohio State University Wexner Medical Center treated with nCRT followed by surgical resection for stage II-III locally advanced, rectal adenocarcinoma from 2004 to 2011. The median follow-up time is 28 months. Patient information was obtained after approval from The Ohio State University institutional review board. Of the 118 patients treated from 2004 to 2011, 26 were excluded due to lack of radiation or chemotherapy details due to being treated outside our institution, leaving 92 patients for the analysis. Clinical staging was performed with physical exam, endoscopy, endorectal ultrasonography, abdominopelvic CT, and/or MRI. All patients received nCRT with the majority receiving 5-FU or capecitabine-based chemotherapy with a median dose of 50.4 Gy radiation in 1.8 Gy daily fractions. Tumors were staged according to AJCC guidelines, based on tumor invasiveness, nodal involvement, and metastasis. Pathologic examination of the surgical specimens was done by institutional pathologists using AJCC criteria to assess response to neoadjuvant therapy. pCR is defined as no residual adenocarcinoma in the surgical specimen.
Given that the timeframe typically recommended as the interval between completion of nCRT and surgical resection is 6 to 10 weeks and based on the recent Dutch analysis, 18 we divided patients into 2 groups midway between our recommended institutional interval: r8 weeks (group A) and >8 weeks (group B) between completion of nCRT and surgery. This dichotomization is consistent with prior published studies. 12, 16, 17 Furthermore, performing the analysis at timepoints other than 8 weeks was limited by loss of statistical power. Time-to-surgery was r8 weeks (group A) in 66 patients (72%; median 6.1 wk; range, 2.7 to 8 wk) and >8 weeks (group B) in 26 patients (28%; median 8.9 wk; range, 8.1 to 17.6 wk). Ninety-one percent (84/ 92) of patients underwent either low-anterior resection or abdominoperineal resection; however, 7% (6/92) underwent other procedures such as transanal excision or total pelvic exenteration. There were only 2 patients for whom the type of surgery was not recorded. Sixty-one percent (56/92) of patients received adjuvant chemotherapy, including FOLFOX, Capecitabine, XELOX, or other chemotherapies. Factors analyzed to ensure balanced characteristics between groups A and B included pretreatment variables (sex, age at diagnosis, clinical T and N stage, abnormal pretreatment CEA level), treatment variables (time interval between completion of nCRT and surgery, radiation dose), and posttreatment variables (pCR, pathologic T and N stage, adjuvant chemotherapy). Clinical and pathologic T and N stages were treated as dichotomized variables for the analysis (T1-2 vs. T3-4; pN0 vs. N1-2). We also grouped patients according to a previously published risk stratification scheme based on a pooled analysis of NCCTG 79-47-51, NCCTG 86-47-51, INT 0114, NSABP R-01, and NSABP R-02. 19 These pathologic risk groupings include low-risk T1-2N0 (L), intermediate-risk T1-2N1/T3N0 (I), moderately highrisk T1-2N2/T3N1/T4N0 (MH), and high-risk T3N2/T4N1/ T4N2 (H). The risk groupings were then dichotomized as lowintermediate risk (LI) versus moderately high-high risk (MHH). Follow-up information was collected, including recurrences (local, regional, and distant) as well as survival data.
Statistical Analysis
Categorical variables between group A and group B were compared using the Fisher exact test. Continuous variables between group A and group B were compared using the Student t test. For each patient, time to locoregional recurrence, distant recurrence, and OS was determined from the date of diagnosis until the date of disease recurrence or death from any cause. Patients lost to follow-up were censored. The Kaplan-Meier estimates, log-rank tests, and Cox proportional regression analyses were used to analyze time to locoregional or distant recurrence, DFS, and OS. SPSS, version 20 (SPSS Inc., Chicago, IL) was used to perform the statistical analyses.
RESULTS
Patient Characteristics
A total of 92 consecutive patients with available radiation and chemotherapy data underwent nCRT followed by surgical resection for stage II-III locally advanced rectal adenocarcinoma. Median follow-up time was 28 months for all patients, as well as for groups A and B. There were 55 (60%) males and 37 (40%) females and the median age was 58.5 years (range, 22 to 88 y). We systematically reviewed the charts for all patients in group B to determine the reasons for delay, and all of the delays except 1 patient appeared to be due to scheduling factors and our institutional acceptance that 6 to 10 weeks is a satisfactory time interval between end of CRT and surgery. One patient in group B had toxicity attributed to nCRT requiring a delay in surgery to 17.6 weeks after nCRT. Another 6 patients in group B had delays beyond 10 weeks only attributable to scheduling issues (range, 10.3 to 16.1 wk). Overall, these 2 groups share similar baseline characteristics (Table 1) . Groups A and B had no significant differences in sex, elevated pretreatment CEA whether dichotomized by 5 ng/ mL or by the mean, radiation dose dichotomized by the median, clinical or pathologic T stage, clinical or pathologic N stage, pathologic risk groupings (LI vs. MHH), tumor location, positive/close margin resection rate, type of surgical resection, and percent of patients receiving adjuvant chemotherapy. Because of limited reporting, we were unable to compare the number of cycles of adjuvant chemotherapy between the 2 groups (or the chemo subgroups) as the numbers of patients in each group (or chemo subgroup) were too small. Finally, there was no significant difference in the pCR rate between the 2 groups, with a total of 16 patients (17.4%) achieving a pCR (18% in group A and 15% in group B, P = 1.0).
Treatment-related Death and Toxicities
To determine whether differences in survival could potentially be related to differences in perioperative or postoperative toxicities/complications, we retrospectively reviewed the charts for deaths in the postoperative period, deaths attributable to surgery, number of hospitalizations, timing of hospitalizations, and reasons for hospitalizations (Table 2) . First, we found no significant differences in the total number of hospitalizations or hospitalizations attributable to therapy between groups A and B. In addition, no significant differences were detected in the number of preoperative hospitalizations (during or after CRT), which occurred in 3% of patients in group A and 7.7% of patients in group B. In terms of surgery-related mortality, no deaths were directly attributable to surgery. The 30-day mortality after surgery was 0% for both groups A and B, indicating no differences between the 2 groups. Likewise, the 90-day mortality rate was 0% for group A and 3.8% (1/26) for group B, which was not statistically significant (P = 0.29). Likewise, no significant differences were identified between groups A and B for the number of postoperative hospitalizations within 30 days, 90 days, within 1 year, between 1 and 3 years, or >3 years. Finally, no significant differences were noted for the indications for hospitalizations among the patients. The most common reasons for hospitalizations occurring at a frequency of Z5% between both groups were infection (related to urinary tract infection/urosepsis), small bowel obstruction, renal obstruction or acute kidney injury, fistula, abscess, anastomotic complications, and need for hernia repair (Table 2) .
Oncologic Outcomes
Of the 92 patients, 11 died during the analysis period (5 patients or 7.5% in group A; 6 patients or 22% in group B). We performed univariate analysis for clinical and pathologic T and N staging, which are the major established prognostic variables in rectal cancer. We found that clinical T and N staging obtained before therapy (comparing cT1-2 vs. cT3-4 or cN0 vs. cN +) was not significantly associated with differences in LRC, distant failure (DF), DFS, or OS. However, consistent with the improved prognostic power of pathologic staging, lower pathologic T stage (pT1-2 vs. pT3-4) was significantly associated with increased LRC (P = 0.01), increased DFS (P < 0.01), decreased DF (P < 0.01), but no difference in OS. In addition, lower nodal pathologic stage (pN0 vs. pN +) was significantly associated with increased DFS (P < 0.01), decreased DF (P < 0.01), but no significant differences were noted for LRC or OS. We then applied previously published risk classifications from a large pooled analysis, which groups patients into low, intermediate, moderately high, and high risk categories, 19 and provides very strong prognostic power compared with traditional T and N staging. Specifically, we dichotomized risk groupings of LI versus MHH, which incorporates both T and N stage and performed univariate analysis. Using these risk groupings, we found strong associations with outcomes, including OS which was not observed even with separate pT and pN stage analysis. LI patients experienced improved DFS (P < 0.05), improved OS (P = 0.01), a trend for decreased DF (P = 0.06), but no difference in LRC compared with MHH patients.
We next performed clinical outcomes analysis of groups A and B to investigate the impact of surgical timing after nCRT. Univariate analysis showed that group B had statistically significantly shorter OS compared with group A (median not reached for group A vs. 52 mo for group B; mean 75 and 50 mo, respectively, P = 0.03) (Fig. 1) . Whereas 2-year OS for groups A and B were similar at 93% to 94%, 4-year OS for groups A and B were substantially different at 88% and 68%, respectively. Univariate analysis also showed that group B had a trend toward shorter DFS compared with group A (median not reached for group A vs. 28 mo for group B; mean 41 and 54 mo, respectively, P = 0.136) (Fig. 2) . When disease relapse was more specifically analyzed as locoregional recurrences versus distant metastases, we found that there was no difference in LRC between both groups. In group A, 7 patients (11%) failed locoregionally and in group B, 4 patients (15%) failed locoregionally (P = 0.51) (Fig. 3A) . However, we detected a statistically significant difference in DF between groups A and B. In group A, 13 patients (20%) failed distantly, compared with group B where 8 patients (31%) failed distantly (median not reached for group A vs. 33 mo for group B, P = 0.047) (Fig. 3B) . In terms of 2-year distant metastasis-free failure, 83% and 71% of patients in groups A and B, respectively, were free of distant metastasis at 2 years, in contrast to 2-year OS numbers. This difference became even more apparent at 4 years, with 70% and 42% of patients in groups A and B, respectively, being free of DF.
Finally, we performed Cox regression multivariate analysis with risk groupings (LI vs. MHH) and time-to-surgery (group A vs. B) in relation to OS, DFS, and DF. We found that with increased time-to-surgery (group B), there is a trend toward decreased OS (P = 0.108, HR = 2.81; 95% CI, 0.80-9.89) and decreased DFS (P = 0.098, HR = 2.08; 95% CI, 0.87-4.94). Finally, in the multivariable model, group B had a significantly decreased time to DF (P = 0.02, HR = 2.96; 95% CI, 1.17-7.50).
DISCUSSION
The current standard of care for locally advanced rectal adenocarcinoma is nCRT followed by surgical resection that typically occurs 6 to 10 weeks after completion of nCRT at many institutions. This has been shown to improve LRC, disease control, and be associated with reduced toxicity based on phase III data. 1,2,5 Despite improvements in LRC with additional perioperative treatments, studies show that the survival rate for patients with locally advanced rectal cancer has not improved with a 5-year OS of about 75%. 1 Current research efforts are seeking novel therapeutic approaches, including different regimens of chemotherapy and radiotherapy or the addition of molecularly targeted therapy, to optimize disease control and improve survival rate. 20 Recently, numerous retrospective studies have suggested that prolonging the interval from nCRT to surgical resection beyond 7 to 8 weeks improves pCR rate, which has been shown in other series to improve outcomes in those receiving nCRT. These studies mostly examined single-institution cohorts in a retrospective manner, and analyzed patients who received nCRT followed by surgical resection. [11] [12] [13] [14] [15] [16] [17] 21 Most of these studies have shown that pCR and downstaging rates increase with surgical delays beyond 7 to 8 weeks. Specifically, pCR rates are 12% to 18% in patients with a shorter time interval to surgery (< 7 to 8 wk), and are 19% to 35% in patients with delayed surgery ( > 8 wk). Some of these studies have also suggested that patients with longer time intervals to surgery had better local control, DFS, and cause-specific survival. 11, 12, 14 Furthermore, a few of these studies retrospectively evaluated toxicity during and after surgery, and cited no increased rates of blood loss, blood transfusions, operative time, postoperative complications, length of hospital stay, or overall morbidity/toxicity with longer interval to surgery, arguing for the safety of this approach. 11, 13, 14, 21 
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Group A Group B FIGURE 1. Overall survival between group A (black, r8 wk) and group B (gray, >8 wk). Log-rank P-value, P = 0.03.
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Group A Group B FIGURE 2. Disease-free survival between group A (black line) and group B (gray line). Log-rank P-value, P = 0.136.
In contrast to prior studies, we did not detect a difference in pCR rates between patients who had surgical resection before or after 8 weeks after completion of nCRT. While our rates of pCR (15% to 18%) are consistent with the published literature, the inability to detect a difference between our 2 patient groups could potentially be explained by the small sample size in this analysis, or confounding variables. Further limitations of our study include potential selection bias and imbalances that are inherent to retrospective reviews. Indeed, group B seemed to have higher T stage than group A, but this was counterbalanced by a lower N stage in group B compared with group A (and the differences were not statistically significant). The strengths of our study include the comparison between patient and tumor characteristics of groups A and B, the inclusion of multivariate modeling, the use of well-validated risk groupings that incorporate both T and N stage established by Gunderson et al, 19 and that careful determination of the causes of delay in group B were scheduling related, and due to our institutional acceptance that a standard interval from end of nCRT to surgery is 6 to 10 weeks.
A major concern in delaying surgery after nCRT is potentially worse outcomes by increasing the risk of tumor dissemination as tumor repopulates. While none of the aforementioned studies reported a detriment to longer interval to surgery, many of them did not perform an outcome analysis or measure rates of DF. While many of them examined DFS, this outcome measures both locoregional and distant control. As we found no differences in LRC between both groups, it is possible that the reason why these studies did not find statistical differences in DFS were due to loss of statistical power from inclusion of LRC data into DFS. We speculate that if the studies separated out DF, this difference might be more commonly noted. That being said, 1 particular retrospective study 12 did report on DF rates and found no differences between the groups examined when using a very similar dichotimization as ours (8 wk). It is not clear to these authors why the disparate findings between our study and theirs. One potential explanation is that most reports suffer from being retrospective analyses, which again have inherent problems with patient selection and potential unidentified imbalances between study groups. In our study, we validated that higher pathologic T stage, N stage, and LI and MHH risk groupings were significantly associated with worse outcomes. Our outcomes analysis not only included DFS, but subdivided the analysis into LRC and DF. We found that delaying surgical resection beyond 8 weeks is associated with an increased rate of DF, which is perhaps the reason for decreased OS and DFS in patients with delayed surgery beyond 8 weeks, as LRC is similar between our 2 groups. In support of this, we observe differences in the development of metastases at 2 years between the 2 groups, which do not translate to significant differences in survival until 3 to 4 years after therapy. This is likely due to effective systemic (and other) therapies that enable continued survival despite development of metastatic disease.
The lack of difference in LRC between both groups is not unexpected. Adequate resection will remove any residual disease in the primary tumor as well as regional lymph nodes, likely making differences in the interval to surgery less relevant with regards to LRC. In the multivariate model, we observed that increased time-to-surgery beyond 8 weeks results in significantly increased DF with trends for decreased survival and DFS being statistically significant in the multivariate analysis. We speculate that the lack of significance in this analysis for DFS may be due to the contributions of LRC to assessing DFS (and hence diluting differences due primarily to DF), relatively effective salvage therapy, relatively low patient numbers, or may be due to imbalances or unseen biases between groups that were not accounted for (and are inherent to retrospective studies). Nevertheless, our data suggest that there might be a potential transition point at about 8 to 10 weeks when cancer cells begin to disseminate from the primary tumor or regional lymphatics after nCRT.
We are not the first to report that delaying surgical resection impacts DF. Recently, using a large, prospectively collected database of almost 1600 patients from the Dutch Surgical Colorectal Audit, Sloothaak et al 18 found that delaying surgery past 10 to 11 weeks after nCRT resulted in the highest rates of pCR (18%) and nodal downstaging (58.6%), which were significantly improved compared with earlier timepoints of <8 weeks, or 8 to 9 weeks. However, they found that delaying time-to-surgery resulted in significantly increased rates of metastatic disease and T4 disease resected beyond 10 to 11 weeks. In fact, the lowest rates of metastatic disease occurred in individuals whose timing to surgery was <9 weeks (rates of 4.4% to 4.8%), whereas at 10 to 11 weeks the rate of A, Locoregional control between group A (black) and group B (gray). Log rank P-value, P = 0.51. B, Distant failure between group A (black) and group B (gray). Log-rank P-value, P < 0.05. metastasis was 8.9%, and further worsened at 14.9% for 12 weeks or beyond (P < 0.001). Unfortunately, the low sample size of our dataset did not permit us to explore similar statistical cutpoints of 9, 10, 11, or 12 weeks. In addition, in comparison with the Dutch study, our data demonstrated rather large differences in DF and potentially OS, which may be more a function of chance in a smaller sample size, or unaccounted for imbalances in T/N stage and risk groupings (despite these not being statistically different). Overall, our data are very consistent with this high-quality, prospective study and argues that the benefit of waiting for further tumor response may at some point be outweighed by the increased development of distant disease beyond 9 weeks. Recently, an oral abstract was presented by Huntington et al 22 at the 2015 Gastrointestinal Cancers Symposium (abstract #510), which showed that in over 6800 rectal cancer patients from the National Cancer Database, delaying surgery resulted in increased rates of pCR. Despite this, delaying surgery beyond 60 days (B8.6 wk) or 75 days (B10.7 wk) was associated with a 20% and 28% increased risk of mortality, respectively, which perhaps is related to the same phenomenon observed in this study. However, these results are preliminary and we await peerreviewed publication of these findings.
As an alternative explanation of our findings, it could be that the time interval from end of CRT or surgery to the start of receiving adjuvant chemotherapy could impact on the development of metastasis by destroying micrometastatic disease or delaying growth/progression of these microscopic cells. Unfortunately, due to inconsistent and limited reporting on details of adjuvant chemotherapy, including the start date of chemotherapy (due in large part to many patients receiving adjuvant chemotherapy closer to home), we are unable to perform this analysis. Overall, the frequency of patients receiving adjuvant chemotherapy was similar between both the groups (61% to 62%). Furthermore, multiple randomized trials, including EORTC22921, Chronicle, and PROCTOR/SCRIPT, examining the role of adjuvant chemotherapy for rectal cancer after curative resection have failed to demonstrate significant clinical improvements. [23] [24] [25] [26] Thus, it seems unlikely that differences in adjuvant chemotherapy start date, type, or number of cycles will account for our observed findings given the benefit of adjuvant chemotherapy in rectal cancer still remains in question.
In terms of future studies, our data may provide support to recommending that surgery occur at 8 to 9 weeks or sooner after nCRT. Alternatively, our data could lend support to the addition of neoadjuvant chemotherapy after the completion of nCRT followed by a short interval (eg, 4 wk) to surgical resection as another way to decrease the risk of distant metastases, while allowing for increased rates of pCR. Indeed, in a phase II trial that explored the addition of FOLFOX chemotherapy after standard nCRT found that rates of pCR increased from 18% to 25%, although the trial was not randomized. 21 In addition, our study and others highlight the need for identifying pretherapy biomarkers that will predict which patients will develop a pCR and/or have a higher likelihood of local failure or DF, allowing us to better determine which patients may or may not benefit from delaying surgery. As a word of caution, however, it is not clear that delaying surgery to improve rates of pCR will translate to improved outcomes. Achieving a pCR most likely simply reflects the inherent favorable biology of a tumor, which would result in improved outcomes, regardless of whether a pCR is achieved before surgical resection. Until a causal relationship between delaying resection to achieve a pCR and improved outcomes is established, achieving a pCR likely simply represents a pathologic prognostic biomarker of favorable disease.
In summary, we confirmed the prognostic utility of pT stage, pN stage, and risk groupings that incorporate T and N staging. In addition, we found that delaying surgical resection beyond 8 weeks is associated with increased rates of DF despite no differences in LRC, with trends toward worse DFS and OS. The findings that delaying surgical resection can result in worse outcomes are corroborated by 2 recent large studies. Given the retrospective nature of our study, we suggest the need for larger prospectively collected data or randomized studies to better clarify the role of the timing of surgery in the setting of nCRT, before delaying surgical resection further to achieve a pCR becomes a common practice.
